Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Amalgamated Bank

Amalgamated Bank boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,125 shares of the specialty pharmaceutical company’s stock after buying an additional 1,745 shares during the period. Amalgamated Bank’s holdings in Jazz Pharmaceuticals were worth $4,176,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Kovack Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 88.8% during the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after purchasing an additional 26,628 shares during the period. John G Ullman & Associates Inc. bought a new position in Jazz Pharmaceuticals during the first quarter valued at about $3,631,000. Swedbank AB bought a new position in Jazz Pharmaceuticals during the second quarter valued at about $106,936,000. Dynamic Technology Lab Private Ltd bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at about $380,000. Finally, Vanguard Group Inc. boosted its stake in Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after buying an additional 84,941 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $110.76 on Friday. The company has a market capitalization of $6.98 billion, a PE ratio of 22.84, a PEG ratio of 1.31 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The company’s 50 day moving average price is $110.79 and its 200 day moving average price is $111.04. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Research analysts expect that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on JAZZ shares. Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. UBS Group decreased their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research note on Tuesday, July 2nd. The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price for the company. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.